Stanford star oncology scientist Ed Engleman helped create the immunotherapy field. Now he wants to shake up neurodegeneration R&D
Over the last generation of drug R&D, Ed Engleman has been a standout scientist.
The Stanford professor co-founded Dendreon and provided the scientific insights needed to develop Provenge into a pioneering — though not particularly marketable — immunotherapy. He’s spurred a slate of startups, assisted by his well-connected perch as a co-founder of Vivo Capital, and took the dendritic cell story into its next chapter at a startup called Bolt.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 91,900+ biopharma pros reading Endpoints daily — and it's free.